Conference Call with Fortis Healthcare Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Fortis Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Consolidated Revenues up 12.4% to Rs 2,007 crore Operating EBITDA up 14.3% to Rs 435 crore, 21.7% Margin (vs Q4FY24 at 21.3%) Hospital Business Revenues up 14.2% to Rs 1,701 crore Operating EBITDA up 11.7% to Rs 372 crore, 21.9% Margin (vs Q4FY24 at 22.4%) FY25 Financial Highlights: Consolidated Revenues up 12.9% to Rs 7,783 crore Operating EBITDA up 25.3% to Rs 1,588 crore, 20.4% Margin (vs FY24 at 18.4%) Hospital Business Revenues up 14.8% to Rs 6,528 crore Operating EBITDA up 26.6% to Rs 1,339 crore, 20.5% Margin (vs FY24 at 18.6%) Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed another year of healthy growth and margin improvement. Noticeable developments during the year included the successful acquisition of the ‘Fortis’ brand and trademarks and our foray into Jalandhar with the signing of definitive agreements in February 2025 to acquire the Shrimann Superspecialty Hospital. The transaction enables us to further strengthen our presence in the Punjab region from approximately 800 beds across four facilities to over 1,000 beds. Aligned to our focus on portfolio rationalization, we divested the business operations of Richmond Road Hospital, Bengaluru in December 2024. Given the strength of our balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.” He further added “In FY25, our hospital business contributed 84% to consolidated revenue compared to 82% in FY24. Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16% YoY and contributed 62% to overall hospital business revenues. The Company consolidated its shareholding in Agilus to 89.2% post the acquisition of 31.5% stake from the PE investors. We have witnessed a steady improvement in the diagnostics business EBITDA margins (excluding one-offs) at 22.0% in FY25 compared to 19.6% in FY24. The new brand is being well accepted and gaining prominence; placing the business in a better position to drive business expansion and enhance performance metrics.” Result PDF
Healthcare Facilities company Fortis Healthcare announced Q3FY25 results Q3FY25 consolidated revenues were at Rs 1,928.3 crore, up 14.8% versus Q3FY24. The operating margins for the quarter were 19.4%, versus 16.9% in the corresponding previous period. Q3FY25 hospital business revenues grew 16.8% to Rs 1,623.1 crore as compared to Rs 1,389.5 crore in Q3FY24. Operating margins stood at 20.0% for the period versus 18.0% in the corresponding previous period. Q3FY25 diagnostic business net revenue were at Rs 305.2 crore versus Rs 290.2 crore in Q3FY24. Operating margins stood at 16.2% for the period versus 11.4% in the corresponding previous period. Excluding one offs, the operating EBITDA margins stood at 23.9% versus 20.8% in Q3FY24. The Company’s net debt as of 31st December 2024 stood at Rs 644 crore with a Net Debt to EBITDA of 0.41x as compared to the 0.45x as on 31st December 2023 (basis Q3 annualized EBITDA). Net debt to equity was at 0.07x versus 0.06x as on 31st December 2023. Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have continued our positive momentum in Q3 with the hospital business contributing approximately 84% to our consolidated revenue and 87% to our consolidated EBITDA. As part of the Company’s portfolio rationalization strategy, we divested business operations of Richmond Road Hospital, Bangalore in December 2024. This divestment supports our focus on improving overall profitability and margins. Leveraging our robust balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.” He further added “Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences contributed 62% to overall hospital business revenues. Among our key specialties, Oncology grew by a strong 30% led by growth of 44% in Hematology and Bone Marrow Transplant, compared to the same period last year. On the diagnostics business, we consolidated our stake by acquiring 31.5% stake from the PE investors, with the Company now holding 89.2% shareholding in Agilus. The diagnostics business performance continues to recover, with an EBITDA margin (excluding one offs) of 21.3%, compared to 18.3% in Q3FY24. However, the business is still impacted by rebranding expenses which we expect will taper off towards the end of the fiscal”. Result PDF